Fennec Pharmaceuticals宣布，其研究者发起的Pedmark®二期临床研究（Sts-J01）在日本的详细结果，将作为口头报告在2026年SIOP（国际儿科肿瘤学会）大会上呈现。这一重要进展，标志着公司在罕见儿科肿瘤治疗领域的又一里程碑。值得注意的是，这项研究并非由公司主导，而是由独立研究者发起并执行，但其结果对于Pedmark®的临床价值验证具有举足轻重的意义。
Fennec Pharmaceuticals宣布，其研究者发起的Pedmark®二期临床研究（Sts-J01）在日本的详细结果，将作为口头报告在2026年SIOP（国际儿科肿瘤学会）大会上呈现。这一重要进展，标志着公司在罕见儿科肿瘤治疗领域的又一里程碑。值得注意的是，这项研究并非由公司主导，而是由独立研究者发起并执行，但其结果对于Pedmark®的临床价值验证具有举足轻重的意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.